Southern Research Scientists to Present New Data at the American Association for Cancer Research 102nd Annual Meeting in Orlando

BIRMINGHAM., Ala., March 29, 2011 /PRNewswire-USNewswire/ -- Southern Research Institute, a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery and drug development today announced that its scientists will be delivering 13 poster presentations at the AACR 102nd Annual Meeting 2011, April 2-6, in Orlando, Fla. Southern Research will also be available to meet with scientists at Booth #543.

Southern Research has discovered more than 20 anti-cancer drugs which have been accepted into clinical trials. Of those, seven have received FDA approval, with six additional drugs currently in late stage preclinical and early clinical trials. Further, Southern Research has evaluated 50 percent of all other FDA-approved cancer drugs on the market. Contract research services include basic research and target identification, lead discovery and optimization, preclinical development and clinical trials support.

Southern Research scientists will present new preclinical data posters in the Exhibit Hall:

Sunday April 3, 2011

1:00 p.m. – 5:00 p.m.

#837:  Novel sulindac derivatives that inhibit colon cancer growth by a cyclooxygenase-independent mechanism involving PDE5 inhibition and the suppression of nuclear Beta-catenin levels   (Exhibit Hall A4-C, Poster Section 34)

Monday April 4, 2011

8:00 a.m. – 12:00 p.m.

#1053:  Mouse Kremen 1 negatively regulates Wnt/Beta-catenin signaling in human breast cancer MDA-MB-231 cells   (Exhibit Hall A4-C, Poster Section 3)

#1853: PDE5 suppression selectively induces apoptosis of human breast tumor cells and attenuates Wnt/Beta-catenin mediated transcription   (Exhibit Hall A4-C, Poster Section 34)

#1865:  Colon cancer chemopreventive properties of a non-cyclooxygenase inhibitory amide derivative of sulindac   (Exhibit Hall A4-C, Poster Section 34)

1:00 p.m. – 5:00 p.m.

#2537:  Novel 2'-deoxycytidine analogs as DNA demethylation agents (Exhibit Hall A4-C, Poster Section 26)

Tuesday April 5, 2011

8:00 a.m. – 12:00 p.m.

#3114:  Effects of tumor-stromal interactions on gene expression in panel of mouse tumor models   (Exhibit Hall A4-C, Poster Section 11)

#3707:  Sulindac sulfide inhibits growth and induces apoptosis of human colon tumor cells by a cGMP-dependent pathway leading to suppression of Beta-catenin transcription activity (Exhibit Hall A4-C, Poster Section 34)

1:00 p.m. – 5:00 p.m.

#4418:  Affymetrix whole genome microarray analysis of 24 human tumor xenograft models and the cell lines from which they were developed: Clustering of targets vs tumor tissue of origin   (Exhibit Hall A4-C, Poster Section 24)

#4265: Bithionol as an inhibitor of tumor angiogenesis (Exhibit Hall A4-C, Poster Section 18)

#3943:  Affymetrix whole genome microarray analysis of 51 human tumor cell lines representative of 16 different tissues of origin: Unsupervised hierarchical clustering

(Exhibit Hall A4-C, Poster Section 6)

#4610:  NO-NSAIDs inhibit colon tumor cell growth by a cGMP-independent mechanism (Exhibit Hall A4-C, Poster Section 33)

Wednesday April 6, 2011

8:00 a.m. – 12:00 p.m.

#5443:  A novel biosensor for monitoring intracellular cGMP in live cells (Exhibit Hall A4-C, Poster Section 29)

#5154: Serotonin signaling as a novel target of tumor angiogenesis (Exhibit Hall A4-C, Poster Section 18)

Southern Research will also have members of its new preclinical, non-invasive imaging team at Booth #543 on hand to discuss this new service.

ABOUT SOUTHERN RESEARCH

Southern Research Institute, founded in 1941, is an independent non-profit organization conducting basic and applied research and development.  More than 530 employees support commercial and government clients and partners in the pharmaceutical, biotechnology, defense, aerospace, environmental and energy sectors through technology out-licensing, sponsored research, and strategic collaborations.  Headquartered in Birmingham, Ala., Southern Research has facilities in Wilsonville, Ala., Frederick, Md., and Durham, NC and offices in Huntsville, Ala., New Orleans, La., Washington, DC and Kiev, Ukraine. For more information about our capabilities, contact us by email at [email protected] or call 888-322-1166 (U.S.) or 1-205-581-2830 (International.)

Contact: Rhonda Jung
205-337-9634
[email protected]

SOURCE Southern Research Institute